This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.
Tablets, Oral, Variable, Twice daily, 48 weeks.
Tablets, Oral, Variable, Twice daily, 48 weeks.
Buenos Aires, Buenos Aires, Argentina
Capital Federal, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Mar del Plata, Buenos Aires, Argentina
Córdoba, Córdoba Province, Argentina
Rosario, Santa Fe Province, Argentina
Buenos Aires, Argentina